Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Danirixin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 known ✓ | P25025 | 20/20 | 1.00 |
| ▸ | CX3CR1 | P49238 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Danirixin SCHEMBL29815122 | 1.00 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| Danirixin SCHEMBL9959547 | 1.00 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| Danirixin SCHEMBL12662221 | 1.00 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| Danirixin SCHEMBL29537761 | 1.00 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| Danirixin SCHEMBL1198688 | 1.00 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL1197995 | 0.94 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL12843897 | 0.94 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL1198597 | 0.91 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL12662220 | 0.91 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL1199231 | 0.91 | CXCR2 (1.00) | CXCR2CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170224679-A1 | Use of CXCR2 Antagonists For The Prevention and/or Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-10 | — | — | US | claimed |
| EP-3174851-A1 | USE OF CXCR2 ANTAGONISTS FOR THE PREVENTION AND/OR TREATMENT OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY (CIPN) | GlaxoSmithKline Intellectual Property Management Limited (GB) | 2017-06-07 | — | — | EP | claimed |
| WO-2016016178-A1 | USE OF CXCR2 ANTAGONISTS FOR THE PREVENTION AND/OR TREATMENT OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY (CIPN) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-02-04 | — | — | WO | claimed |
| EP-2009992-B1 | IL-8 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2012-06-27 | — | — | EP | claimed |
| US-20110105563-A1 | IL-8 RECEPTOR ANTAGONISTS | BUSCH-PETERSEN JAKOB | 2011-05-05 | — | — | US | claimed |
| US-20110059937-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION | 2011-03-10 | — | — | US | claimed |
| US-7893089-B2 | IL-8 receptor antagonists | GlaxoSmithKline, LLC (US) | 2011-02-22 | — | — | US | claimed |
| US-20090093451-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-09 | — | — | US | claimed |
| EP-2009992-A2 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2007124424-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-01 | — | — | WO | claimed |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | NOVARTIS AG (CH) | 2026-05-19 | — | — | US | disclosed |
| US-12600777-B2 | Combination therapies comprising antibody molecules to LAG-3 | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| US-12479817-B2 | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2025-11-25 | — | — | US | disclosed |
| US-20250289802-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2025-09-18 | — | — | US | disclosed |
| US-7893089-B2 | IL-8 receptor antagonists | GlaxoSmithKline, LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090093451-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-09 | — | — | US | disclosed |
| EP-2009992-A2 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007124424-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249672-A1 | IL-8 Receptor Antagonists | GLAXOSMITHKLINE LLC | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479817-B2 | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, RXFP3, NPY2R | CXCR2 107/4885CX3CR1 1157/4885 |
| US-20110105563-A1 | IL-8 RECEPTOR ANTAGONISTS | CXCL8, CCR8, IL1RN | CXCR2 12/4885CX3CR1 33/4885 |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | CXCR2 219/4885CX3CR1 1321/4885 |
| US-12600777-B2 | Combination therapies comprising antibody molecules to LAG-3 | IGSF11, IGLV6-57, CD2 | CXCR2 3967/4885CX3CR1 1292/4885 |
| US-20170224679-A1 | Use of CXCR2 Antagonists For The Prevention and/or Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) | CXCR2, CXCR3, CCR2 | CXCR2 1/4885CX3CR1 15/4885 |
| US-20070249672-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | CXCR2 12/4885CX3CR1 33/4885 |
| US-20110059937-A1 | IL-8 RECEPTOR ANTAGONISTS | CXCL8, CCR8, IL1RN | CXCR2 12/4885CX3CR1 33/4885 |
| US-20250289802-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | AVPR2, RXFP3, OPRD1 | CXCR2 586/4885CX3CR1 2402/4885 |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | CD40, CD274, ICOS | CXCR2 346/4885CX3CR1 136/4885 |
| US-20090093451-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | CXCR2 12/4885CX3CR1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.